Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tam

Showing results (861-870 of 922) with videos related to

Pageof 93
Sort By:
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Lancet (London, England)|August 2, 2003
Newly discovered coronavirus as the primary cause of severe acute respiratory syndromeThijs Kuiken, Ron A M Fouchier, Martin Schutten, et al.
Transplantation and Cellular Therapy|March 9, 2026
A computerised cognitive test for immune effector cell-associated neurotoxicity syndrome in chimeric antigen receptor T-cell therapy recipients: a pilot studyChristina Kazzi, David Darby, Miriam Wronski, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Blood|March 12, 2020
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencingPrasath Pararajalingam, Krysta M Coyle, Sarah E Arthur, et al.
Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.
Blood|October 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemiaMeng-Xiao Luo, Tania Tan, Marie Trussart, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Pageof 93

Showing results (861-870 of 922) with videos related to

Sort By:
Pageof 93
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Lancet (London, England)|August 2, 2003
Newly discovered coronavirus as the primary cause of severe acute respiratory syndromeThijs Kuiken, Ron A M Fouchier, Martin Schutten, et al.
Transplantation and Cellular Therapy|March 9, 2026
A computerised cognitive test for immune effector cell-associated neurotoxicity syndrome in chimeric antigen receptor T-cell therapy recipients: a pilot studyChristina Kazzi, David Darby, Miriam Wronski, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Transplantation and Cellular Therapy|March 27, 2026
Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Blood|March 12, 2020
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencingPrasath Pararajalingam, Krysta M Coyle, Sarah E Arthur, et al.
Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.
Blood|October 29, 2024
Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemiaMeng-Xiao Luo, Tania Tan, Marie Trussart, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Pageof 93